pilaralisib,
SAR 245408,
SAR245408,
XL147,
XL147,
956958-53-5,
XL147 analogue,
PI3K inhibitor X,
XL 147,
Pilaralisib analogue,
N-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide,
N-[3-(2,1,3-Benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methylbenzenesulfonamide,
CHEBI:71957,
C21H16N6O2S2,
N-(3-(benzo[c][1,2,5]thiadiazol-5-ylamino)quinoxalin-2-yl)-4-methylbenzenesulfonamide,
Benzenesulfonamide, N-[3-(2,1,3-benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methyl-,
1033110-57-4,
PubChem22457,
XL-147 derivative 2,
cc-43,
AC1LZ6F0,
AC1Q2LO8,
Oprea1_361507,
GTPL7963,
SCHEMBL1792641,
XL147-II,
CHEMBL3218575,
AOB5431,
DTXSID10145779,
SYN1127,
HMS3654E06,
BCP01861,
EX-A1362,
ZINC2267166,
ABP000084,
AN-530,
MFCD16621245,
s1118,
STL325024,
XL147 analogue(PI3K inhibitor X),
XL147/XL-147,
AKOS015842552,
AKOS022131419,
CS-0088,
MCULE-9777093020,
PB33271,
QC-1903,
RL06023,
NCGC00346492-01,
AC-23168,
BC660050,
HY-11105,
SC-85909,
AB0008192,
FT-0662582,
SW219812-1,
X7417,
EC-000.2364,
J3.553.988C,
A20590,
Q-4583,
N-[3-(2,
J-519683,
BRD-K95901403-001-01-1,
N-[3-(2,1,3-Benzothiadiazol-5-ylamino)-2-quinoxali,
XL 147, XL-147, 956958-53-5,
N-[3-(2,1,3-Benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methylbenzenesulfonamide,,
N-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methyl-benzenesulfonamide,
N-[3-(2,1,3-benzothiadiazol-6-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide,
SAR245408;N-(3-(benzo[c][1,2,5]thiadiazol-5-ylamino)quinoxalin-2-yl)-4-methylbenzenesulfonamide,
XL-147|||N-[3-(2,1,3-Benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide,
Pilaralisib,
XL-147,
SAR245408,
D02IZS,
D03KAC,
ZSTK474,
SAR-245408,
RW3070,
ZINC02267166,
ACN-037797,
CID1893730,
A5112,
SAR245408 + MSC1936369B,
A10995,
934526-89-3,